287(top 100%)
PR articles
37.6K(top 1%)
PR citations
79(top 100%)
PR h-index
84(top 100%)
h-index
317
documents
49.0K
doc citations
4.6K
citing journals
100
times ranked

Publications

291 PR articles • 40,742 PR citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | PR Citations
#ArticleIFPR CitationsLinks
1Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report
American Journal of Respiratory and Critical Care Medicine, 2024, 209, 362-373
12.212Citations (PDF)
2Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial
American Journal of Respiratory and Critical Care Medicine, 2024, 209, 1132-1140
12.237Citations (PDF)
3Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort
JCI Insight, 2024, 9,
5.40Citations (PDF)
4COPD Exacerbations Before and During COVID-19 in France, Germany, Italy, the UK and the US
International Journal of COPD, 2024, Volume 19, 1433-1445
2.84Citations (PDF)
5RIOK2 transcriptionally regulates TRiC and dyskerin complexes to prevent telomere shortening
Nature Communications, 2024, 15,
13.94Citations (PDF)
6Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease
Rheumatology, 2023, 62, 1877-1886
2.013Citations (PDF)
7Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies
Journal of Asthma and Allergy, 2023, Volume 16, 333-342
2.85Citations (PDF)
8High versus Medium Dose of Inhaled Corticosteroid in Chronic Obstructive Lung Disease: A Systematic Review and Meta-Analysis
International Journal of COPD, 2023, Volume 18, 469-482
2.88Citations (PDF)
9Validity and Reliability of the Fatigue Severity Scale in a Real-World Interstitial Lung Disease Cohort
American Journal of Respiratory and Critical Care Medicine, 2023, 208, 188-195
12.221Citations (PDF)
10Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial
American Journal of Respiratory and Critical Care Medicine, 2023, 208, 417-427
12.234Citations (PDF)
11Repeatability of Pulmonary Quantitative Computed Tomography Measurements in Chronic Obstructive Pulmonary Disease
American Journal of Respiratory and Critical Care Medicine, 2023, 208, 657-665
12.227Citations (PDF)
12Approach to Clinical Trials for the Prevention of Pulmonary Fibrosis
Annals of the American Thoracic Society, 2023, 20, 1683-1693
3.88Citations (PDF)
13Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre–Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward
American Journal of Respiratory and Critical Care Medicine, 2022, 205, 275-287
12.2147Citations (PDF)
14Alpha-1 Antitrypsin MZ Heterozygosity Is an Endotype of Chronic Obstructive Pulmonary Disease
American Journal of Respiratory and Critical Care Medicine, 2022, 205, 313-323
12.239Citations (PDF)
15Significance of FEV3/FEV6 in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD
Chest, 2022, 161, 949-959
1.125Citations (PDF)
16Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial
American Journal of Respiratory and Critical Care Medicine, 2022, 205, 674-684
12.2106Citations (PDF)
17Cystic Fibrosis Transmembrane Conductance Regulator: Roles in Chronic Obstructive Pulmonary Disease
American Journal of Respiratory and Critical Care Medicine, 2022, 205, 631-640
12.228Citations (PDF)
18Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort
Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2022, 9, 111-121
0.914Citations (PDF)
19Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial)
American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1084-1092
12.220Citations (PDF)
20CONQUEST: A Quality Improvement Program for Defining and Optimizing Standards of Care for Modifiable High-Risk COPD Patients
Patient Related Outcome Measures, 2022, Volume 13, 53-68
1.75Citations (PDF)
21Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
Respirology, 2022, 27, 294-300
4.141Citations (PDF)
22Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective
American Journal of Respiratory and Critical Care Medicine, 2022, 206, 247-259
12.224Citations (PDF)
23Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
Respiratory Research, 2022, 23,
4.540Citations (PDF)
24International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials
American Journal of Respiratory and Critical Care Medicine, 2022, 206, 25-33
12.220Citations (PDF)
25Ambient ozone effects on respiratory outcomes among smokers modified by neighborhood poverty: An analysis of SPIROMICS AIR
Science of the Total Environment, 2022, 829, 154694
8.412Citations (PDF)
26Lung tissue shows divergent gene expression between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis
Respiratory Research, 2022, 23,
4.527Citations (PDF)
27Rare and Common Variants in <i>KIF15</i> Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis
American Journal of Respiratory and Critical Care Medicine, 2022, 206, 56-69
12.250Citations (PDF)
28Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
American Journal of Respiratory and Critical Care Medicine, 2022, 205, e18-e47
12.22,189Citations (PDF)
29Lung Microbiota and Metabolites Collectively Associate with Clinical Outcomes in Milder Stage Chronic Obstructive Pulmonary Disease
American Journal of Respiratory and Critical Care Medicine, 2022, 206, 427-439
12.276Citations (PDF)
30Transbronchial Lung Cryobiopsy in Patients with Interstitial Lung Disease: A Systematic Review
Annals of the American Thoracic Society, 2022, 19, 1193-1202
3.884Citations (PDF)
31Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study
American Journal of Respiratory and Critical Care Medicine, 2022, 206, 554-562
12.238Citations (PDF)
32Relationship between prior inhaled corticosteroid use and benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study
Respiratory Medicine, 2022, 197, 106857
2.814Citations (PDF)
33Risk of COPD exacerbation is increased by poor sleep quality and modified by social adversity
Sleep, 2022, 45,
1.019Citations (PDF)
34Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review
American Journal of Respiratory and Critical Care Medicine, 2022, 206, 17-24
12.2126Citations (PDF)
35Predictive modeling of COPD exacerbation rates using baseline risk factors
Therapeutic Advances in Respiratory Disease, 2022, 16,
2.823Citations (PDF)
36A Phase IIb Randomized Clinical Study of an Anti-α<sub>v</sub>β<sub>6</sub> Monoclonal Antibody in Idiopathic Pulmonary Fibrosis
American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1128-1139
12.278Citations (PDF)
37Prevalence and Mechanisms of Mucus Accumulation in COVID-19 Lung Disease
American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1336-1352
12.262Citations (PDF)
38Pharmacotherapy and Mortality in Chronic Obstructive Pulmonary Disease
American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1201-1207
12.214Citations (PDF)
39Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
International Journal of COPD, 2022, Volume 17, 1633-1642
2.83Citations (PDF)
40Utility of whole genome sequencing in assessing risk and clinically relevant outcomes for pulmonary fibrosis
European Respiratory Journal, 2022, 60, 2200577
12.138Citations (PDF)
41Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis
Respiratory Medicine, 2022, 205, 107040
2.811Citations (PDF)
42Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS
International Journal of COPD, 2022, Volume 17, 3061-3073
2.820Citations (PDF)
43Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease
American Journal of Respiratory and Critical Care Medicine, 2021, 203, 24-36
12.2628Citations (PDF)
44Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia
American Journal of Respiratory and Critical Care Medicine, 2021, 203, 211-220
12.276Citations (PDF)
45Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD
Chest, 2021, 159, 985-995
1.18Citations (PDF)
46Contribution of Individual and Neighborhood Factors to Racial Disparities in Respiratory Outcomes
American Journal of Respiratory and Critical Care Medicine, 2021, 203, 987-997
12.264Citations (PDF)
47Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review
American Journal of Respiratory and Critical Care Medicine, 2021, 203, 689-698
12.273Citations (PDF)
48Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis
American Journal of Respiratory and Critical Care Medicine, 2021, 203, 458-470
12.247Citations (PDF)
49Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers
American Journal of Respiratory and Critical Care Medicine, 2021, 203, 957-968
12.2150Citations (PDF)
50Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study
American Journal of Respiratory and Critical Care Medicine, 2021, 203, 553-564
12.2228Citations (PDF)
51Quantitative Emphysema on Low-Dose CT Imaging of the Chest and Risk of Lung Cancer and Airflow Obstruction
Chest, 2021, 159, 1812-1820
1.160Citations (PDF)
52Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment
Respiratory Medicine, 2021, 176, 106278
2.88Citations (PDF)
53Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis
ERJ Open Research, 2021, 7, 00663-2020
2.612Citations (PDF)
54Natural history and mechanisms of <scp>COPD</scp>
Respirology, 2021, 26, 298-321
4.192Citations (PDF)
55Polycythemia is Associated with Lower Incidence of Severe COPD Exacerbations in the SPIROMICS Study
Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2021, 8, 326-335
0.95Citations (PDF)
56Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS
International Journal of COPD, 2021, Volume 16, 179-189
2.816Citations (PDF)
57Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort
Npj Biofilms and Microbiomes, 2021, 7,
8.157Citations (PDF)
58Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells
American Journal of Respiratory and Critical Care Medicine, 2021, 204, 197-208
12.241Citations (PDF)
59The influence of social support on COPD outcomes mediated by depression
PLoS ONE, 2021, 16, e0245478
2.425Citations (PDF)
60Latent traits of lung tissue patterns in former smokers derived by dual channel deep learning in computed tomography images
Scientific Reports, 2021, 11,
3.515Citations (PDF)
61InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations
Respiratory Research, 2021, 22,
4.521Citations (PDF)
62Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort
Respiratory Research, 2021, 22,
4.523Citations (PDF)
63Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium
Genome Medicine, 2021, 13,
9.734Citations (PDF)
64Longitudinal Imaging-Based Clusters in Former Smokers of the COPD Cohort Associate with Clinical Characteristics: The SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)
International Journal of COPD, 2021, Volume 16, 1477-1496
2.812Citations (PDF)
65Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort
Lancet Respiratory Medicine,the, 2021, 9, 1241-1254
24.2165Citations (PDF)
66Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial
ERJ Open Research, 2021, 7, 00902-2020
2.641Citations (PDF)
67Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial
Pulmonary Therapy, 2021, 7, 471-486
2.841Citations (PDF)
68Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study
Journal of Heart and Lung Transplantation, 2021, 40, 494-503
1.229Citations (PDF)
69Future concepts in bronchodilation for COPD: dual- <i>versus</i> monotherapy
European Respiratory Review, 2021, 30, 210023
8.710Citations (PDF)
70Reversal of emphysema by restoration of pulmonary endothelial cells
Journal of Experimental Medicine, 2021, 218,
9.480Citations (PDF)
71Ratio of FEV1/Slow Vital Capacity of &lt; 0.7 Is Associated With Clinical, Functional, and Radiologic Features of Obstructive Lung Disease in Smokers With Preserved Lung Function
Chest, 2021, 160, 94-103
1.115Citations (PDF)
72Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement
American Journal of Respiratory and Critical Care Medicine, 2021, 204, e3-e23
12.277Citations (PDF)
73Identifying organ dysfunction trajectory-based subphenotypes in critically ill patients with COVID-19
Scientific Reports, 2021, 11,
3.525Citations (PDF)
74Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial
Respiratory Medicine, 2021, 185, 106509
2.819Citations (PDF)
75Barriers to antigen detection and avoidance in chronic hypersensitivity pneumonitis in the United States
Respiratory Research, 2021, 22,
4.518Citations (PDF)
76CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care
International Journal of COPD, 2021, Volume 16, 2301-2322
2.824Citations (PDF)
77Racial Segregation and Respiratory Outcomes among Urban Black Residents with and at Risk of Chronic Obstructive Pulmonary Disease
American Journal of Respiratory and Critical Care Medicine, 2021, 204, 536-545
12.230Citations (PDF)
78Does Evaluation and Management of COPD Follow Therapeutic Strategy Recommendations?
Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2021, 8, 230-242
0.95Citations (PDF)
79InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions
Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2021, 8, 76-90
0.91Citations (PDF)
80Protocol Summary of the COPD Assessment in Primary Care To Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE) Validation in Primary Care Study
Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2021, 8, 60-75
0.99Citations (PDF)
81Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler <i>versus</i> dual therapies in patients with COPD: a sub-study of the ETHOS trial
Therapeutic Advances in Respiratory Disease, 2021, 15,
2.824Citations (PDF)
82Epigenetic marker of telomeric age is associated with exacerbations and hospitalizations in chronic obstructive pulmonary disease
Respiratory Research, 2021, 22,
4.511Citations (PDF)
83The Effects of Rare <i>SERPINA1</i> Variants on Lung Function and Emphysema in SPIROMICS
American Journal of Respiratory and Critical Care Medicine, 2020, 201, 540-554
12.251Citations (PDF)
84Association of Long-term Ambient Ozone Exposure With Respiratory Morbidity in Smokers
JAMA Internal Medicine, 2020, 180, 106
10.867Citations (PDF)
85Host, Gender, and Early-Life Factors as Risks for Chronic Obstructive Pulmonary Disease
Clinics in Chest Medicine, 2020, 41, 329-337
3.610Citations (PDF)
86Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial
Respiratory Research, 2020, 21,
4.522Citations (PDF)
87Increased airway iron parameters and risk for exacerbation in COPD: an analysis from SPIROMICS
Scientific Reports, 2020, 10,
3.526Citations (PDF)
88Current smoking with or without chronic bronchitis is independently associated with goblet cell hyperplasia in healthy smokers and COPD subjects
Scientific Reports, 2020, 10,
3.59Citations (PDF)
89Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities
Lancet Respiratory Medicine,the, 2020, 8, 925-934
24.2304Citations (PDF)
90Identification of a unique temporal signature in blood and BAL associated with IPF progression
Scientific Reports, 2020, 10,
3.515Citations (PDF)
91&lt;p&gt;Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the Spiromics Cohort&lt;/p&gt;
International Journal of COPD, 2020, Volume 15, 1887-1898
2.85Citations (PDF)
92&lt;p&gt;Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort&lt;/p&gt;
International Journal of COPD, 2020, Volume 15, 2467-2476
2.815Citations (PDF)
93Serum IgG Levels and Risk of COPD Hospitalization
Chest, 2020, 158, 1420-1430
1.134Citations (PDF)
94Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD
ERJ Open Research, 2020, 6, 00187-2019
2.67Citations (PDF)
95Update in Interstitial Lung Disease 2019
American Journal of Respiratory and Critical Care Medicine, 2020, 202, 500-507
12.230Citations (PDF)
96Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies
Respiratory Research, 2020, 21,
4.56Citations (PDF)
97&lt;p&gt;FEV&lt;sub&gt;1&lt;/sub&gt; is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease&lt;/p&gt;
International Journal of COPD, 2020, Volume 15, 1135-1142
2.858Citations (PDF)
98Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults
JAMA - Journal of the American Medical Association, 2020, 323, 2268
17.1173Citations (PDF)
99Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD
New England Journal of Medicine, 2020, 383, 35-48
43.7528Citations (PDF)
100Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease
American Journal of Respiratory and Critical Care Medicine, 2020, 202, 660-671
12.287Citations (PDF)
101Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease
American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1508-1516
12.2214Citations (PDF)
102Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment
Thorax, 2020, 75, 735-743
5.826Citations (PDF)
103The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial
American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1237-1243
12.237Citations (PDF)
104A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD
Respiratory Research, 2020, 21,
4.556Citations (PDF)
105A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis
Chest, 2020, 157, 1506-1512
1.151Citations (PDF)
106&lt;p&gt;Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies&lt;/p&gt;
International Journal of COPD, 2020, Volume 15, 99-106
2.83Citations (PDF)
107Association of Guideline-Recommended COPD Inhaler Regimens With Mortality, Respiratory Exacerbations, and Quality of Life
Chest, 2020, 158, 529-538
1.110Citations (PDF)
108Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease
BMJ Open Respiratory Research, 2020, 7, e000392
2.6104Citations (PDF)
109Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline
American Journal of Respiratory and Critical Care Medicine, 2020, 201, e56-e69
12.2266Citations (PDF)
110The natural history of progressive fibrosing interstitial lung diseases
European Respiratory Journal, 2020, 55, 2000085
12.1224Citations (PDF)
111Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort
JCI Insight, 2020, 5,
5.440Citations (PDF)
112An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup
Journal of Clinical Investigation, 2019, 129, 169-181
10.796Citations (PDF)
113Voxel-Wise Longitudinal Parametric Response Mapping Analysis of Chest Computed Tomography in Smokers
Academic Radiology, 2019, 26, 217-223
2.873Citations (PDF)
114Clinical Approach to the Therapy of Asthma-COPD Overlap
Chest, 2019, 155, 168-177
1.155Citations (PDF)
115Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis
American Journal of Respiratory and Critical Care Medicine, 2019, 199, 12-21
12.2146Citations (PDF)
116Serum amino acid concentrations and clinical outcomes in smokers: SPIROMICS metabolomics study
Scientific Reports, 2019, 9,
3.528Citations (PDF)
117Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE)
American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1505-1512
12.258Citations (PDF)
118Imaging-based clusters in former smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and intermediate outcome measures in COPD study (SPIROMICS)
Respiratory Research, 2019, 20,
4.533Citations (PDF)
119Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial
Lancet Respiratory Medicine,the, 2019, 7, 745-756
24.2202Citations (PDF)
120Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis
American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153
12.268Citations (PDF)
121Metoprolol for the Prevention of Acute Exacerbations of COPD
New England Journal of Medicine, 2019, 381, 2304-2314
43.7156Citations (PDF)
122Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes
Scientific Reports, 2019, 9,
3.516Citations (PDF)
123Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study
Lancet Respiratory Medicine,the, 2019, 7, 780-790
24.2217Citations (PDF)
124A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol
Respiratory Medicine, 2019, 158, 59-66
2.835Citations (PDF)
125Spirometric indices of early airflow impairment in individuals at risk of developing COPD: Spirometry beyond FEV1/FVC
Respiratory Medicine, 2019, 156, 58-68
2.864Citations (PDF)
126Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial
BMJ Open Respiratory Research, 2019, 6, e000431
2.635Citations (PDF)
127Inference of Cellular Immune Environments in Sputum and Peripheral Blood Associated with Acute Exacerbations of COPD
Cellular and Molecular Bioengineering, 2019, 12, 165-177
1.95Citations (PDF)
128Diagnosis and management of asthma, COPD and asthma‐COPD overlap among primary care physicians and respiratory/allergy specialists: A global survey
Clinical Respiratory Journal, 2019, 13, 355-367
2.212Citations (PDF)
129Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019
European Respiratory Journal, 2019, 53, 1900164
12.11,584Citations (PDF)
130A Genetic Risk Score Associated with Chronic Obstructive Pulmonary Disease Susceptibility and Lung Structure on Computed Tomography
American Journal of Respiratory and Critical Care Medicine, 2019, 200, 721-731
12.246Citations (PDF)
131Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study
Lancet Respiratory Medicine,the, 2019, 7, 497-508
24.2223Citations (PDF)
132Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study
Lancet Respiratory Medicine,the, 2019, 7, 487-496
24.2150Citations (PDF)
133The characterisation of interstitial lung disease multidisciplinary team meetings: a global study
ERJ Open Research, 2019, 5, 00209-2018
2.667Citations (PDF)
134Noninvasive Imaging Biomarker Identifies Small Airway Damage in Severe Chronic Obstructive Pulmonary Disease
American Journal of Respiratory and Critical Care Medicine, 2019, 200, 575-581
12.2147Citations (PDF)
135Systemic Markers of Inflammation in Smokers With Symptoms Despite Preserved Spirometry in SPIROMICS
Chest, 2019, 155, 908-917
1.125Citations (PDF)
136Reprint of: Voxel-Wise Longitudinal Parametric Response Mapping Analysis of Chest Computed Tomography in Smokers
Academic Radiology, 2019, 26, 306-312
2.813Citations (PDF)
137Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis
American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1127-1138
12.2314Citations (PDF)
138‘It’s difficult, it’s life changing what happens to you’ patient perspective on life with chronic hypersensitivity pneumonitis: a qualitative study
BMJ Open Respiratory Research, 2019, 6, e000522
2.616Citations (PDF)
139Relationship between diffusion capacity and small airway abnormality in COPDGene
Respiratory Research, 2019, 20,
4.534Citations (PDF)
140Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS
Annals of the American Thoracic Society, 2019, 16, 200-208
3.839Citations (PDF)
141Why Does an Aging Smoker’s Lung Develop Idiopathic Pulmonary Fibrosis and Not Chronic Obstructive Pulmonary Disease?
American Journal of Respiratory and Critical Care Medicine, 2019, 199, 279-285
12.229Citations (PDF)
142Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis
American Journal of Respiratory and Critical Care Medicine, 2019, 200, 336-347
12.2150Citations (PDF)
143Effects of baseline symptom burden on treatment response in COPD
International Journal of COPD, 2019, Volume 14, 181-194
2.88Citations (PDF)
144Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee
Annals of the American Thoracic Society, 2019, 16, 29-39
3.817Citations (PDF)
145Closing the Evidence Gap in Interstitial Lung Disease. The Promise of Real-World Data
American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1061-1065
12.210Citations (PDF)
146Safety and Tolerability of Comprehensive Research Bronchoscopy in Chronic Obstructive Pulmonary Disease. Results from the SPIROMICS Bronchoscopy Substudy
Annals of the American Thoracic Society, 2019, 16, 439-446
3.826Citations (PDF)
147Hypersensitivity Pneumonitis
Chest, 2019, 155, 699-711
1.1198Citations (PDF)
148Pulmonary hypertension in chronic lung disease and hypoxia
European Respiratory Journal, 2019, 53, 1801914
12.1625Citations (PDF)
149Mortality and Exacerbations by Global Initiative for Chronic Obstructive Lung Disease Groups ABCD: 2011 Versus 2017 in the COPDGene® Cohort
Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2019, 6, 64-73
0.928Citations (PDF)
150COPDGene® 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2019, 6, 384-399
0.9139Citations (PDF)
151β-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT
Annals of the American Thoracic Society, 2018, 15, 608-614
3.825Citations (PDF)
152Patient-reported Outcomes for the Detection, Quantification, and Evaluation of Chronic Obstructive Pulmonary Disease Exacerbations
American Journal of Respiratory and Critical Care Medicine, 2018, 198, 730-738
12.232Citations (PDF)
153Update in Chronic Obstructive Pulmonary Disease 2017
American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1534-1539
12.23Citations (PDF)
154Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
New England Journal of Medicine, 2018, 378, 1671-1680
43.71,065Citations (PDF)
155Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A <i>Post Hoc</i> Cohort Analysis from the SUMMIT Randomized Clinical Trial
American Journal of Respiratory and Critical Care Medicine, 2018, 198, 51-57
12.2307Citations (PDF)
156Human airway branch variation and chronic obstructive pulmonary disease
Proceedings of the National Academy of Sciences of the United States of America, 2018, 115,
7.6108Citations (PDF)
157At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease
American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1540-1551
12.2254Citations (PDF)
158Efficacy and safety profile of xanthines in COPD: a network meta-analysis
European Respiratory Review, 2018, 27, 180010
8.745Citations (PDF)
159Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD
Respiratory Research, 2018, 19,
4.544Citations (PDF)
160Rural Residence and Chronic Obstructive Pulmonary Disease Exacerbations. Analysis of the SPIROMICS Cohort
Annals of the American Thoracic Society, 2018, 15, 808-816
3.840Citations (PDF)
161Alveolar eosinophilia in current smokers with chronic obstructive pulmonary disease in the SPIROMICS cohort
Journal of Allergy and Clinical Immunology, 2018, 141, 429-432
6.220Citations (PDF)
162Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey
American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1036-1044
12.2197Citations (PDF)
163A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis
Chest, 2018, 153, 94-104
1.190Citations (PDF)
164Centrilobular emphysema and coronary artery calcification: mediation analysis in the SPIROMICS cohort
Respiratory Research, 2018, 19,
4.528Citations (PDF)
165Heterogeneous burden of lung disease in smokers with borderline airflow obstruction
Respiratory Research, 2018, 19,
4.512Citations (PDF)
166Confronting the Challenge of COPD
Chest, 2018, 154, 984-985
1.19Citations (PDF)
167Imaging-based clusters in current smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)
Respiratory Research, 2018, 19,
4.523Citations (PDF)
168Focus on Idiopathic Pulmonary Fibrosis
Chest, 2018, 154, 978-979
1.114Citations (PDF)
169Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial
Lancet Respiratory Medicine,the, 2018, 6, 747-758
24.2320Citations (PDF)
170Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
American Journal of Respiratory and Critical Care Medicine, 2018, 198, e44-e68
12.23,529Citations (PDF)
171Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials
American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1268-1278
12.266Citations (PDF)
172Development and validation of a radiological diagnosis model for hypersensitivity pneumonitis
European Respiratory Journal, 2018, 52, 1800443
12.169Citations (PDF)
173Genome-wide association study of lung function and clinical implication in heavy smokers
BMC Medical Genetics, 2018, 19,
2.036Citations (PDF)
174Precision medicine in COPD: where are we and where do we need to go?
European Respiratory Review, 2018, 27, 180022
8.776Citations (PDF)
175Relationship of Absolute Telomere Length With Quality of Life, Exacerbations, and Mortality in COPD
Chest, 2018, 154, 266-273
1.125Citations (PDF)
176Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease
Journal of the American College of Cardiology, 2018, 72, 1126-1137
2.461Citations (PDF)
177Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial
European Heart Journal, 2018, 39, 3128-3134
2.347Citations (PDF)
178Can CAPTURE be used to identify undiagnosed patients with mild-to-moderate COPD likely to benefit from treatment?
International Journal of COPD, 2018, Volume 13, 1901-1912
2.814Citations (PDF)
179Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial
Lancet Respiratory Medicine,the, 2018, 6, 707-714
24.2129Citations (PDF)
180Chronic obstructive pulmonary disease subpopulations and phenotyping
Journal of Allergy and Clinical Immunology, 2018, 141, 1961-1971
6.271Citations (PDF)
181NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort
Respiratory Medicine, 2018, 140, 87-93
2.826Citations (PDF)
182Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPDGene
JCI Insight, 2018, 3,
5.468Citations (PDF)
183A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease
Respiratory Research, 2017, 18,
4.522Citations (PDF)
184Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report
Respirology, 2017, 22, 575-601
4.1321Citations (PDF)
185Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary
European Respiratory Journal, 2017, 49, 1700214
12.1601Citations (PDF)
186Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary
American Journal of Respiratory and Critical Care Medicine, 2017, 195, 557-582
12.22,742Citations (PDF)
187Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis
American Journal of Respiratory and Critical Care Medicine, 2017, 196, 208-219
12.2148Citations (PDF)
188GDF-15 plasma levels in chronic obstructive pulmonary disease are associated with subclinical coronary artery disease
Respiratory Research, 2017, 18,
4.532Citations (PDF)
189Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk
Heart, 2017, 103, 1536-1542
4.346Citations (PDF)
190A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective
American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1249-1254
12.2206Citations (PDF)
191Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis
Chest, 2017, 151, 1173-1174
1.114Citations (PDF)
192Serum IgG and risk of exacerbations and hospitalizations in chronic obstructive pulmonary disease
Journal of Allergy and Clinical Immunology, 2017, 140, 1164-1167.e6
6.238Citations (PDF)
193Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort
Annals of the American Thoracic Society, 2017, 14, 636-642
3.832Citations (PDF)
194The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes
Scientific Reports, 2017, 7,
3.556Citations (PDF)
195Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD
Chest, 2017, 151, 340-357
1.199Citations (PDF)
196Informe 2017 de la Iniciativa Global para el Diagnóstico, Tratamiento y Prevención de la Enfermedad Pulmonar Obstructiva Crónica: Resumen Ejecutivo de GOLD
Archivos De Bronconeumologia, 2017, 53, 128-149
1.5331Citations (PDF)
197The diagnosis of idiopathic pulmonary fibrosis: current and future approaches
Lancet Respiratory Medicine,the, 2017, 5, 61-71
24.299Citations (PDF)
198Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial
Lancet Respiratory Medicine,the, 2017, 5, 22-32
24.2247Citations (PDF)
199Diagnosis and Treatment of Fibrotic Hypersensitivity Pneumonia. Where We Stand and Where We Need to Go
American Journal of Respiratory and Critical Care Medicine, 2017, 196, 690-699
12.2210Citations (PDF)
200Design of the Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS) AIR Study
BMJ Open Respiratory Research, 2017, 4, e000186
2.624Citations (PDF)
201Idiopathic pulmonary fibrosis
Nature Reviews Disease Primers, 2017, 3,
50.71,179Citations (PDF)
202Targeting the vascular and perivascular niches as a regenerative therapy for lung and liver fibrosis
Science Translational Medicine, 2017, 9,
12.7107Citations (PDF)
203Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case–cohort study
European Respiratory Journal, 2017, 50, 1700936
12.190Citations (PDF)
204Possible UIP pattern on high-resolution computed tomography is associated with better survival than definite UIP in IPF patients
Respiratory Medicine, 2017, 131, 229-235
2.830Citations (PDF)
205Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD
Chest, 2017, 152, 1169-1178
1.137Citations (PDF)
206Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial
Respiratory Medicine, 2017, 131, 27-34
2.832Citations (PDF)
207Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort
Lancet Respiratory Medicine,the, 2017, 5, 956-967
24.2276Citations (PDF)
208Usual Interstitial Pneumonia Can Be Detected in Transbronchial Biopsies Using Machine Learning
Annals of the American Thoracic Society, 2017, 14, 1646-1654
3.886Citations (PDF)
209Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort
Lancet Respiratory Medicine,the, 2017, 5, 619-626
24.2276Citations (PDF)
210Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori
Respiratory Research, 2017, 18,
4.57Citations (PDF)
211Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD)
Respiratory Research, 2017, 18,
4.533Citations (PDF)
212The Role of Chest Computed Tomography in the Evaluation and Management of the Patient with Chronic Obstructive Pulmonary Disease
American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1372-1379
12.2132Citations (PDF)
213Idiopathic Pulmonary Fibrosis: The Association between the Adaptive Multiple Features Method and Fibrosis Outcomes
American Journal of Respiratory and Critical Care Medicine, 2017, 195, 921-929
12.2127Citations (PDF)
214Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction
American Journal of Respiratory and Critical Care Medicine, 2017, 195, 881-888
12.251Citations (PDF)
215A New Approach for Identifying Patients with Undiagnosed Chronic Obstructive Pulmonary Disease
American Journal of Respiratory and Critical Care Medicine, 2017, 195, 748-756
12.2134Citations (PDF)
216Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts
American Journal of Respiratory and Critical Care Medicine, 2017, 195, 473-481
12.2115Citations (PDF)
217Chronic Respiratory Symptoms with Normal Spirometry. A Reliable Clinical Entity?
American Journal of Respiratory and Critical Care Medicine, 2017, 195, 17-22
12.247Citations (PDF)
218Variability in objective and subjective measures affects baseline values in studies of patients with COPD
PLoS ONE, 2017, 12, e0184606
2.427Citations (PDF)
219Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus
Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2017, 4, 7-20
0.910Citations (PDF)
220Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study
Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2017, 4, 21-33
0.95Citations (PDF)
221Correcting Nonpathological Variation in Longitudinal Parametric Response Maps of CT Scans in COPD Subjects: SPIROMICS
Tomography, 2017, 3, 138-145
2.04Citations (PDF)
222Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting &amp;beta;&lt;sub&gt;2&lt;/sub&gt;-agonist fixed-dose combination: RE&lt;sup&gt;2&lt;/sup&gt;SPOND rationale and study design
International Journal of COPD, 2016, Volume 11, 1921-1928
2.811Citations (PDF)
223Insight into Best Variables for COPD Case Identification: A Random Forests Analysis
Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2016, 3, 406-418
0.915Citations (PDF)
224Understanding the impact of second-hand smoke exposure on clinical outcomes in participants with COPD in the SPIROMICS cohort
Thorax, 2016, 71, 411-420
5.826Citations (PDF)
225Age-Related Differences in Health-Related Quality of Life in COPD
Chest, 2016, 149, 927-935
1.149Citations (PDF)
226Integrated Genomics Reveals Convergent Transcriptomic Networks Underlying Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis
American Journal of Respiratory and Critical Care Medicine, 2016, 194, 948-960
12.2120Citations (PDF)
227Plasma Surfactant Protein-D, Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias
American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1242-1251
12.2163Citations (PDF)
228Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function
New England Journal of Medicine, 2016, 374, 1811-1821
43.7625Citations (PDF)
229A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD
Respiratory Medicine, 2016, 120, 16-24
2.819Citations (PDF)
230Predictors of idiopathic pulmonary fibrosis in absence of radiologic honeycombing: A cross sectional analysis in ILD patients undergoing lung tissue sampling
Respiratory Medicine, 2016, 118, 88-95
2.846Citations (PDF)
231SPIROMICS Protocol for Multicenter Quantitative Computed Tomography to Phenotype the Lungs
American Journal of Respiratory and Critical Care Medicine, 2016, 194, 794-806
12.2232Citations (PDF)
232Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease
American Journal of Respiratory and Critical Care Medicine, 2016, 194, 541-549
12.276Citations (PDF)
233Development of the chronic obstructive pulmonary disease morning symptom diary (COPD-MSD)
Health and Quality of Life Outcomes, 2016, 14,
3.09Citations (PDF)
234Meeting the challenge of COPD care delivery in the USA: a multiprovider perspective
Lancet Respiratory Medicine,the, 2016, 4, 473-526
24.290Citations (PDF)
235Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
American Journal of Respiratory and Critical Care Medicine, 2016, 194, 265-275
12.21,248Citations (PDF)
236Idiopathic Pulmonary Fibrosis
Chest, 2016, 149, 491-498
1.196Citations (PDF)
237Association between Functional Small Airway Disease and FEV<sub>1</sub> Decline in Chronic Obstructive Pulmonary Disease
American Journal of Respiratory and Critical Care Medicine, 2016, 194, 178-184
12.2366Citations (PDF)
238The Microbiome and the Respiratory Tract
Annual Review of Physiology, 2016, 78, 481-504
17.2814Citations (PDF)
239Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD
PLoS Genetics, 2016, 12, e1006011
3.395Citations (PDF)
240Six-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPF
PLoS ONE, 2016, 11, e0159878
2.450Citations (PDF)
241The Human Microbiome in the Lung: Are Infections Contributing to Lung Health and Disease?
Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2016, 3, 466-472
0.911Citations (PDF)
242Integrative phenotyping framework (iPF): integrative clustering of multiple omics data identifies novel lung disease subphenotypes
BMC Genomics, 2015, 16,
3.399Citations (PDF)
243Identifying cases of undiagnosed, clinically significant COPD in primary care: qualitative insight from patients in the target population
Npj Primary Care Respiratory Medicine, 2015, 25,
4.315Citations (PDF)
244Acute exacerbations of chronic obstructive pulmonary disease are associated with decreased CD4+ &amp; CD8+ T cells and increased growth &amp; differentiation factor-15 (GDF-15) in peripheral blood
Respiratory Research, 2015, 16,
4.555Citations (PDF)
245The Impact of Sources of Variability on Parametric Response Mapping of Lung CT Scans
Tomography, 2015, 1, 69-77
2.027Citations (PDF)
246Parametric Response Mapping Monitors Temporal Changes on Lung CT Scans in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)
Academic Radiology, 2015, 22, 186-194
2.8100Citations (PDF)
247Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial
Lancet, The, 2015, 385, 857-866
52.8339Citations (PDF)
248Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD
Annals of the American Thoracic Society, 2015, 12, 27-34
3.8142Citations (PDF)
249An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline
American Journal of Respiratory and Critical Care Medicine, 2015, 192, e3-e19
12.21,718Citations (PDF)
250Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials
Lancet Respiratory Medicine,the, 2015, 3, 388-396
24.277Citations (PDF)
251Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management
Lancet, The, 2015, 385, 1789-1798
52.8226Citations (PDF)
252A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials
European Respiratory Journal, 2015, 46, 243-249
12.151Citations (PDF)
253Heart Failure and Respiratory Hospitalizations Are Reduced in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease With the Use of an Implantable Pulmonary Artery Pressure Monitoring Device
Journal of Cardiac Failure, 2015, 21, 240-249
1.954Citations (PDF)
254CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab
European Respiratory Journal, 2015, 46, 1740-1750
12.1130Citations (PDF)
255<i>TOLLIP</i>, <i>MUC5B</i>, and the Response to <i>N</i>-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis
American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1475-1482
12.2304Citations (PDF)
256Older Adults with Chronic Lung Disease Report Less Limitation Compared with Younger Adults with Similar Lung Function Impairment
Annals of the American Thoracic Society, 2015, 12, 21-26
3.821Citations (PDF)
257Basal Gene Expression by Lung CD4+ T Cells in Chronic Obstructive Pulmonary Disease Identifies Independent Molecular Correlates of Airflow Obstruction and Emphysema Extent
PLoS ONE, 2014, 9, e96421
2.424Citations (PDF)
258Human CD56+ Cytotoxic Lung Lymphocytes Kill Autologous Lung Cells in Chronic Obstructive Pulmonary Disease
PLoS ONE, 2014, 9, e103840
2.455Citations (PDF)
259Inflammatory Leukocyte Phenotypes Correlate with Disease Progression in Idiopathic Pulmonary Fibrosis
Frontiers in Medicine, 2014, 1,
2.651Citations (PDF)
260Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS): Table 1
Thorax, 2014, 69, 492-495
5.8346Citations (PDF)
261Cell-associated bacteria in the human lung microbiome
Microbiome, 2014, 2,
11.571Citations (PDF)
262Smoking-related idiopathic interstitial pneumonia
European Respiratory Journal, 2014, 44, 594-602
12.139Citations (PDF)
263Analysis of Culture-Dependent versus Culture-Independent Techniques for Identification of Bacteria in Clinically Obtained Bronchoalveolar Lavage Fluid
Journal of Clinical Microbiology, 2014, 52, 3605-3613
4.1157Citations (PDF)
264The role of the microbiome in exacerbations of chronic lung diseases
Lancet, The, 2014, 384, 691-702
52.8446Citations (PDF)
265Study Design Implications of Death and Hospitalization as End Points in Idiopathic Pulmonary Fibrosis
Chest, 2014, 146, 1256-1262
1.129Citations (PDF)
266Changes in the Lung Microbiome following Lung Transplantation Include the Emergence of Two Distinct Pseudomonas Species with Distinct Clinical Associations
PLoS ONE, 2014, 9, e97214
2.4174Citations (PDF)
267Identifying Patients with Undiagnosed COPD in Primary Care Settings: Insight from Screening Tools and Epidemiologic Studies
Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2014, 2, 103-121
0.941Citations (PDF)
268Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
American Journal of Respiratory and Critical Care Medicine, 2013, 187, 347-365
12.27,074Citations (PDF)
269Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials
Lancet Respiratory Medicine,the, 2013, 1, 369-376
24.2369Citations (PDF)
270Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan
Annals of Internal Medicine, 2013, 158, 641
10.4512Citations (PDF)
271MMP Mediated Degradation of Type IV Collagen Alpha 1 and Alpha 3 Chains Reflects Basement Membrane Remodeling in Experimental and Clinical Fibrosis – Validation of Two Novel Biomarker Assays
PLoS ONE, 2013, 8, e84934
2.4168Citations (PDF)
272An Assessment of Epithelial and Mesenchymal Phenotypes in Experimental and Clinical Pulmonary Fibrosis
ISRN Pulmonology, 2012, 2012, 1-11
0.50Citations (PDF)
273Relationship Between Lung Function Impairment and Health-Related Quality of Life in COPD and Interstitial Lung Disease
Chest, 2012, 142, 704-711
1.132Citations (PDF)
274Prednisone, Azathioprine, and<i>N</i>-Acetylcysteine for Pulmonary Fibrosis
New England Journal of Medicine, 2012, 366, 1968-1977
43.71,533Citations (PDF)
275The future of chronic obstructive pulmonary disease treatment—difficulties of and barriers to drug development
Lancet, The, 2011, 378, 1027-1037
52.887Citations (PDF)
276Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension
Journal of the American College of Cardiology, 2009, 54, S85-S96
2.4357Citations (PDF)
277Development and Initial Validation of a Self-Scored COPD Population Screener Questionnaire (COPD-PS)
COPD: Journal of Chronic Obstructive Pulmonary Disease, 2008, 5, 85-95
2.1227Citations (PDF)
278Accuracy of High-Resolution CT in the Diagnosis of Diffuse Lung Disease: Effect of Predominance and Distribution of Findings
American Journal of Roentgenology, 2008, 191, 1032-1039
4.272Citations (PDF)
279Sex Differences in Severe Pulmonary Emphysema
American Journal of Respiratory and Critical Care Medicine, 2007, 176, 243-252
12.2331Citations (PDF)
280Predictors of Mortality in Patients with Emphysema and Severe Airflow Obstruction
American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1326-1334
12.2409Citations (PDF)
281Is it asthma or COPD?
Postgraduate Medicine, 2005, 117, 19-26
2.827Citations (PDF)
282Surgical Therapy for Chronic Obstructive Pulmonary Disease
Seminars in Respiratory and Critical Care Medicine, 2005, 26, 167-191
2.445Citations (PDF)
283Acute exacerbation of chronic bronchitis: expanding short-course therapy
International Journal of Antimicrobial Agents, 2005, 26, S156-S163
4.06Citations (PDF)
284Idiopathic Interstitial Pneumonia
American Journal of Respiratory and Critical Care Medicine, 2004, 170, 904-910
12.2616Citations (PDF)
285Acute bronchitis: State of the art diagnosis and therapy
Comprehensive Therapy, 2004, 30, 55-69
0.316Citations (PDF)
286Patient selection for lung volume reduction surgery
Chest Surgery Clinics of North America, 2003, 13, 669-685
1.48Citations (PDF)
287Diagnosing chronic obstructive pulmonary disease
Postgraduate Medicine, 1998, 103, 112-125
2.816Citations (PDF)
288Use of a Genomic Classifier in Patients with Interstitial Lung Disease: A Systematic Review
Annals of the American Thoracic Society, 0, ,
3.814Citations (PDF)
289Research priorities to address the global burden of chronic obstructive pulmonary disease (COPD) in the next decade
Journal of Global Health, 0, 11,
2.938Citations (PDF)
290Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT Trial
Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 0, ,
0.97Citations (PDF)
291Characterizing COPD Symptom Variability in the Stable State Utilizing the Evaluating Respiratory Symptoms in COPD Questionnaire
Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 0, ,
0.91Citations (PDF)